Agents for intravitreal administration to treat or prevent disorders of the eye
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A vitreous and reagent technology, applied in the field of medicaments and antimetabolites for the treatment or prevention of certain ophthalmic diseases, can solve problems such as retinal detachment or tear, blood vessel hemorrhage, danger, etc.
Inactive Publication Date: 2002-10-30
透明视网膜技术公司
View PDF4 Cites 4 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, this type of vitreous extraction is very technical and is associated with several significant disadvantages, dangers, and complications
Among the disadvantages, risks and complications, the act of removing the vitreous may further cause detachment or tearing of the retina and / or such removal of the vitreous will further cause bleeding of already fragile blood vessels
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 8
[0071]Example 8 Urea USP / NF 4.0% Hyaluronidase 1.0IU-100IU Sodium Chloride USP / NF Up to 0.9% Sterile Water for Injection USP Q.S. The pH of 100% solution is 5.0-7.0 (PH uses 0.1N hydrochloric acid / 0.1 hydrogen Sodium oxide adjustment) Example 9 Urea USP / NF 0.01%-15.0% Hyaluronidase 1.0IU-100IU Sodium Chloride USP / NF Up to 0.9% Sterile Water for Injection USP Q.S. pH 5.0-7.0 of 100% solution (PH Adjust with 0.1N hydrochloric acid / 0.1N sodium hydroxide)
Embodiment 10
[0072] Example 10 Urea USP / NF 0.01%-15.0% Urokinase 1.0IU-50IU Sodium Chloride USP / NF Up to 0.9% Sterile Water for Injection USP Q.S. The pH of 100% solution is 5.0-7.0 (PH uses 0.1N hydrochloric acid / 0.1 N NaOH adjustment)
Embodiment 11
[0073] Example 11 Urea USP / NF 0.01%-15.0% Chondroitinase (Chondroitinase) ABC 1.0IU-30IU Sodium Chloride USP / NF Up to 0.9% Sterile Water for Injection USP Q.S. pH 5.0-7.0 of 100% solution (for pH 0.1N hydrochloric acid / 0.1 sodium hydroxide adjustment)
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The present invention relates to methods and formulations for treating ophthalmic diseases and / or causing posterior vitreous separation or detachment. Preparations containing a) urea, b) urea derivatives (e.g. hydroxyurea, thiourea), c) non-steroidal anti-inflammatory agents, d) antimetabolites, e) urea, urea derivatives, non-enzymatic proteins, nuclear Glycosides, nucleotides and their derivatives (such as adenine, adenosine, cytosine, cytidine, guanine, guanidine, guanidine salt, thymidine, thymidine, uracil, uracil, cystine ), uric acid, aspirin calcium, ammonium sulfate or other compounds capable of causing non-enzymatic dissolution of the vitreous membrane, or e) any possible combination thereof; the preparation is administered into the eye in a therapeutically effective amount.
Description
field of invention [0001] The present invention relates broadly to pharmaceutical preparations and methods of medical treatment, in particular agents (i.e. urea or urea derivatives, non-steroidal anti-inflammatory drugs (NSAIDS) and antimetabolites). Background of the invention [0002] A. Neovascularization [0003] Neovascularization (or angiogenesis) is the process by which new blood vessels are formed in body tissues. Normal neovascularization is the physiological process by which the body creates and maintains the small blood vessels of the circulatory system. However, pathological or iatrogenic neovascularization is the non-physiological process by which abnormal vascular networks are formed in body tissues or in tumors, leading to certain diseases, traumas or other surgical conditions. [0004] Pathological neovascularization in ocular tissue is the result of certain ophthalmic diseases, such as diabetic retinopathy, proliferative vitreoretino...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more